Literature DB >> 30144475

Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria.

Tessa Niemeyer-van der Kolk1, Maurits S van Maaren2, Martijn B A van Doorn3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30144475     DOI： 10.1016/j.jaci.2018.07.032

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  7 in total

1.  Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.

Authors:  Rachel L Miller; Maria Shtessel; Lacey B Robinson; Aleena Banerji
Journal:  J Allergy Clin Immunol       Date:  2019-06-24       Impact factor: 10.793

2.  Prospective analysis of clinical evolution in chronic urticaria: Persistence, remission, recurrence, and pruritus alone.

Authors:  Jorge Sánchez; Leidy Álvarez; Ricardo Cardona
Journal:  World Allergy Organ J       Date:  2022-10-08       Impact factor: 5.516

3.  Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

Authors:  Coco Dekkers; Mehran Alizadeh Aghdam; Marlies de Graaf; André C Knulst; Yolanda Meijer; Juul M P A van den Reek; Marike B Stadermann; Heike Röckmann
Journal:  Pediatr Allergy Immunol       Date:  2021-01-18       Impact factor: 6.377

Review 4.  Autoimmune Theories of Chronic Spontaneous Urticaria.

Authors:  Sonali J Bracken; Soman Abraham; Amanda S MacLeod
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

5.  Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.

Authors:  Mehran Alizadeh Aghdam; Edward F Knol; Mignon van den Elzen; Constance den Hartog Jager; Harmieke van Os-Medendorp; André C Knulst; Henny G Otten; Heike Röckmann
Journal:  Clin Exp Allergy       Date:  2020-02-07       Impact factor: 5.018

6.  Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.

Authors:  Yudi Chen; Miao Yu; Xiaojie Huang; Ping Tu; Peikun Shi; Marcus Maurer; Zuotao Zhao
Journal:  World Allergy Organ J       Date:  2021-01-05       Impact factor: 4.084

Review 7.  Pediatric usage of Omalizumab: A promising one.

Authors:  Lin Yu; Huishan Zhang; Jianwei Pan; Leping Ye
Journal:  World Allergy Organ J       Date:  2021-12-11       Impact factor: 4.084
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.